About MicroTech Medical
Established in 2011, MicroTech Medical is located in the Hangzhou Future Sci-Tech City, which is the leading venture technology park in Hangzhou. Shortly after, the US R&D center was established in California’s Silicon Valley.
MicroTech’s management and technical teams were recruited from all over the world, with the majority of the group having post-secondary, graduate and/or post-graduate university degrees as well as extensive experience in medical technology.
MicroTech’s certifications include regulatory approvals for CE and CFDA, as well as product conformity to ISO 15197:2015 (BGMS products) and IEC 60601-2-24 (pump therapy products). In 2013, the government designated MicroTech as Lead Diabetes Research Center in Zhejiang Province.
MicroTech Medical is devoted to innovation in chronic disease management, and strives to bring to market healthcare products globally. The company’s portfolio includes therapy products such as the Equil Patch Insulin Pump and diagnostic products such as the AiDEX Continuous Glucose Monitoring System (CGMS), multiple lines of Blood Glucose Monitoring Systems (BGMS), and POCT products.
With the help this line of products, MicroTech Medical continues to allow more freedom, flexibility, and choice to those who are limited by chronic disease.
MicroTech’s management and technical teams were recruited from all over the world, with the majority of the group having post-secondary, graduate and/or post-graduate university degrees as well as extensive experience in medical technology.
MicroTech’s certifications include regulatory approvals for CE and CFDA, as well as product conformity to ISO 15197:2015 (BGMS products) and IEC 60601-2-24 (pump therapy products). In 2013, the government designated MicroTech as Lead Diabetes Research Center in Zhejiang Province.
MicroTech Medical is devoted to innovation in chronic disease management, and strives to bring to market healthcare products globally. The company’s portfolio includes therapy products such as the Equil Patch Insulin Pump and diagnostic products such as the AiDEX Continuous Glucose Monitoring System (CGMS), multiple lines of Blood Glucose Monitoring Systems (BGMS), and POCT products.
With the help this line of products, MicroTech Medical continues to allow more freedom, flexibility, and choice to those who are limited by chronic disease.
Financials Beta
Business Model: Not Specified
Revenues: $44 Million - $132 Million / year
Expenses: $44 Million - $132 Million / year
Debt: Request
Operating Status: Active
Funding Raised: $156 Million
Investment Rounds: 4 Rounds
Funding Stage: Series D
Last Funding Date: Series D
Investors
Funding Rounds
Funding
Funding Rounds
D
$88,000,000
Series D Round
Late Stage
Dec 2020
C
$30,000,000
Series C Round
Growth Stage
Dec 2018
B
$13,000,000
Series B Round
Growth Stage
Jan 2017
A
$25,000,000
Series A Round
Early Stage
Feb 2016
